What AbCellera Biologics Inc. does.

AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates. While we historically used our platform for our partners’ programs, we have evolved our strategy to build our own internal pipeline of AbCellera-owned drug assets.

• Initiated clinical trials for our first two internal drug candidates , ABCL635 and ABCL575. Our lead candidate, ABCL635, is a potential first-in-class non-hormonal medicine for moderate-to-severe vasomotor symptoms (VMS), also known as hot flashes. It is currently being evaluated in a Phase 2 clinical trial in Canada for the treatment of moderate-to-severe VMS associated with menopause, and we anticipate the topline data readout for the Phase 1/2 study in Q3 2026. Our second clinical candidate, ABCL575, is being evaluated in a Phase 1 clinical trial in Canada as a potential best-in-class medicine for the treatment of atopic dermatitis and other inflammation and immunology (I&I) conditions. We anticipate the topline data readout for the Phase 1 study of ABCL575 in Q4 2026.

Revenue and profit, by fiscal year.

More on ABCL.

• AbCellera Biologics Inc. summary
• AbCellera Biologics Inc. financial statements
• AbCellera Biologics Inc. key metrics
• AbCellera Biologics Inc. health scores and style box
• AbCellera Biologics Inc. earnings
• AbCellera Biologics Inc. dividends
• AbCellera Biologics Inc. valuation
• AbCellera Biologics Inc. ownership and insiders
• AbCellera Biologics Inc. peers

Figures from AbCellera Biologics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.